Marvel Adds Celebrity Oxygen to Weakening Franchise Formulas
Ryan Gosling is joining Ghost Rider, David Jonsson is joining Black Panther. The trade press has settled on the narrative that Marvel Studios is finally abandoning its exhausted IP formula and betting on A-list talent instead.
Except both actors are being cast into existing characters with decades of comic book weight behind them. Ghost Rider didn't become a franchise vehicle because studios fell in love with Ryan Gosling's potential—Gosling was brought in because Ghost Rider alone could no longer carry a film.
The same logic applies to Jonsson. This isn't a departure from IP dependency—it's IP dependency with a blood transfusion. Marvel's problem isn't that audiences reject sequels and IP films generally. The MCU still generates billions on franchise recognition alone.
The problem is specific. Standalone character introductions have stopped working. Black Panther 3 isn't casting a hot young actor because the studio discovered talent beats IP—it's casting because Black Panther 3, coming after Chadwick Boseman's death and two years of audience fatigue, needs something IP cannot provide anymore. A name. A gravitational pull that has nothing to do with whether you know who T'Challa is.
This is what addiction looks like: you don't switch substances, you add more of a different substance to the old one because the original dose stopped working.
”The studio is saying that pure IP—the accumulated world-building, the team-up potential, the interconnected narrative—is no longer sufficient oxygen for a film to breathe. So now every moderately risky MCU entry requires celebrity as structural support. This is what addiction looks like. You don't switch substances, you add more of a different substance to the old one because the original dose stopped working. The mistake in reading this as talent-driven casting is assuming the studio made a choice. In reality, Marvel responded to a market signal.
When your IP generates guaranteed revenue but mediocre openings, you're not pivoting. You're doubling down on the only variable you haven't exhausted yet. That applies to more than superhero franchises. Every business that feels its core product weakening reaches for a celebrity or a name or an external validation rather than examining why the product itself stopped resonating. The casting announcement feels like an innovation because something had to change.
Pick a recent casting announcement from any major studio and ask: Is this talent-driven innovation or addiction-driven compensation? Check if the underlying IP showed weakening box office before the star was attached.
